JHOP - March 2019 Vol 9, No 1

Amy Kamien, PharmD, BCOP; Ana Knuth, RPh; Cheruppolil Santhosh-Kumar, MD

Effectiveness of a Single 6-mg Fixed Dose of Rasburicase for Prevention or Management of Hyperuricemia Associated with Tumor Lysis Syndrome in Adults with Cancer

Mansoor Ahmed Khan, BS, MS, BCOP; Majed A. Alshamrani, PharmD, BCPS, BCOP; Mohammed A. Aseeri, PharmD, BCPS, FISMP; Ahmad S. Al Saeed, MD; Hani S. Alhamdan, BS, MS; Ahlam O. Masari, MD

Sterility Duration of Single-Use Vials for Antineoplastic Agents or Monoclonal Antibodies Extended with a Closed-System Transfer Device

Major Rosalynda Uy, PharmD, BCPS; Michael S. Edwards, PharmD, MBA, BCOP, FASHP; Dominic A. Solimando, Jr, MA, BCOP, FAPhA, FASHP

Review Article

Olanzapine for Prevention or Management of Chemotherapy-Induced Nausea and Vomiting: A Promising Option

Osama Al-Quteimat, MSc, BCOP; Jeffrey Tollison, RPh, BSPharm, BCPS; Mohammad Aslam Siddiqui, PharmD, MBA, CPHIMS

From the Literature

Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy

ASH Highlights

Meeting Highlights

Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies

Charles Bankhead, Medical Writer

Meeting Highlights

MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL

Phoebe Starr, Medical Writer

Meeting Highlights

Researchers Identify First Mutation to Explain Resistance to Venetoclax

Phoebe Starr, Medical Writer

Meeting Highlights

Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy

Phoebe Starr, Medical Writer

Meeting Highlights

Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas

Phoebe Starr, Medical Writer

Meeting Highlights

First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with CLL

Wayne Kuznar, Medical Writer

JHOP - March 2019 Vol 9, No 1

Subscribe Today!

I'd like to receive: